The urokinase plasminogen activator receptor (uPAR) represents one of the emerging attractive tumor targets for such targeted therapy due to its sparse expression in healthy homeostatic tissues compared to the robust expression in most solid tumors [4,5]. The gene discussed is PLAUR; the disease is neoplasm.